c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems

Journal of Clinical Oncology

Volumn 18, Issue 11, 2000, Pages 2201-2209

  Allgayer, Heike ^a   Babic, Rudolf ^a   Gruetzner, Klaus Uwe ^a   Tarabichi, Anwar ^a   Schildberg, Friedrich Wilhelm ^a   Heiss, Markus Maria ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 MACROGLOBULIN; ANTITHROMBIN III; ONCOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEINASE; PROTEINASE INHIBITOR; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER;

EID: 0034118639     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.11.2201     Document Type: Article

References (64)

1. Yamamoto T, Ikawa S, Akiyama T, et al: Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 319:230-236, 1986
2. Akiyama T, Sudo C, Ogawara H, et al: The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646, 1986
3. Slamon DJ, Godolphin W, Jones L, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
4. Hynes N, Stern D: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165-184, 1994
5. Fukushige S, Matsubara K, Yoshida M, et al: Localisation of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 6:955-958, 1986
6. Bongiorno PF, Whyte RI, Lesser EJ, et al: Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J Thorac Cardiovasc Surg 107:590-595, 1994
7. Mitra AB, Murty VVS, Pratap M, et al: ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 54:637-639, 1994
8. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 235:177-182, 1987
9. Beckhardt RN, Kiyokawa N, Liu TJ, et al: Neu oncogene in head and neck squamous cell carcinoma. Proc Am Assoc Cancer Res 35:153, 1994
10. Yu D, Hung MC: Expression of ras neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 6:1991-1996, 1991
11. Tan M, Yao J, Yu D: Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57:1199-1205, 1997
12. Gum R, Wang Shang-Wu, Lengyel E, et al: Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. Anticancer Res 15:1167-1172, 1995
13. Ossowski L, Clunie G, Masucci MT, et al: In vivo paracrine interaction between urokinase and its receptor: Effect on tumor cell invasion. J Cell Biol 115:1107-1112, 1991
14. Blasi F: Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 15:105-111, 1993
15. Heiss MM, Babic R, Allgayer H, et al: Tumor associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 13:2084-2093, 1995
16. Graeff H, Harbeck N, Pache O, et al: Prognostic impact and clinical relevance of tumor-associated proteases in breast cancer. Fibrinolysis 6:45-53, 1992
17. Pedersen H, Gondrahl-Hansen J, Francis D, et al: Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54:120-123, 1994
18. Jänicke F, Schmitt M, Pache L, et al: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993
19. Allgayer H, Babic R, Gruetzner KU, et al: Tumor-associated proteases and inhibitors in gastric cancer: Analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis 16:62-73, 1998
20. Guerin M, Gabillot M, Mathieu MC, et al: Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: Prognostic significance. Int J Cancer 43:201-208, 1989
21. Van de Vijiver MJ, Peterse JL, Mooi WJ, et al: Neu protein overexpression in breast cancer: Association with comedo type-ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245, 1988
22. Berger MS, Locher GW, Sauer S, et al: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243, 1988
23. Park JW, Colbern G, Hong K, et al: Targeted intracellular drug delivery via anti-HER2 immunoliposomes yields superior antitumor efficacy. Proc Am Soc Clin Oncol 16:430a, 1997 (abstr)
24. Uchino S, Tsuda H, Maruyama K, et al: Overexpression of c-erbB-2 protein in gastric cancer. Cancer 72:3179-3184, 1993
25. Chariyalertsak S, Sugano K, Okhura H, et al: Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer. Tumor Biol 15:294-303, 1994
26. Mizutani T, Onda M, Tokunaga A, et al: Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 72:2083-2088, 1993
27. Hilton D, West K: c-erbB-2 oncogene product expression and prognosis in gastric carcinoma. J Clin Pathol 45:454-456, 1992
28. Kolodziejczyk P, Yao T, Oya M, et al: Long term follow-up study of patients with gastric adenomas with malignant transformation. Cancer 74:2896-2907, 1994
29. Tateishi M, Toda T, Minamisono Y, et al: Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. Surg Oncol 49:209-212, 1992
30. Sasano H, Date F, Imatani A, et al: Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 24:584-589, 1993
31. Allgayer H, Babic R, Gruetzner KU, et al: An immunohistochemical assessment of cathepsin D in gastric carcinoma: Its impact on clinical prognosis. Cancer 80:179-187, 1997
32. Heiss MM, Babic R, Allgayer H, et al: The prognostic impact of the urokinase-type plasminogen activator system is associated with tumor differentiation in gastric cancer. Eur J Surg Oncol 22:74-77, 1996
33. Heiss MM, Allgayer H, Gruetzner KU, et al: Individual development and uPA-receptor expression of disseminated tumor cells in bone marrow: A reference to early systemic disease in solid cancer. Nat Med 1:1035-1039, 1995
34. Allgayer H, Babic R, Beyer BC, et al: Prognostic relevance MMP-2 (72-kD collagenase IV) in gastric cancer. Oncology 55:152-160, 1998
35. Holm S: A simple sequentially rejective multiple test procedure. Scand J Stat 6:65-70, 1979
36. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
37. Cox DR: Regression models and life tables. J Stat Soc 34:187-220, 1972
38. Dixon WJ, Brown MB, Engelman L, et al: BMDP Statistical Software. Berkeley, CA, University of California Press, 1985
39. Adenis A, Huet G, Zerimech F, et al: Cathepsin B, L and D activities in colorectal carcinomas: Relationship with clinico-pathological parameters. Cancer Lett 96:267-275, 1995
40. Schmitt M, Jaenicke F, Graeff H: Tumor-associated proteases. Fibrinolysis 6:3-26, 1992
41. Dvorak HF: Tumors: Wounds that do not heal. N Engl J Med 315:1650-1659, 1986
42. Liotta LA: Tumor invasion and metastases: Role of the extracellular matrix - Roads Memorial Award lecture. Cancer Res 46:1-7, 1986
43. Dano K, Andreasen PA, Grondahl-Hansen J, et al: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44:139-266, 1985
44. Yonemura Y, Ninimiya I, Ohoyama S, et al: Expression of c-erbB-2 oncoprotein in gastric carcinoma. Cancer 67:2914-2918, 1991
45. Yonemura Y, Niniomiya I, Yamaguchi A, et al: Evaluation of immunoreactivity for erbB-2 protein as a marker for poor short term prognosis in gastric cancer. Cancer Res 51:1034-1038, 1991
46. Yonemura Y, Ninomiya I, Ohoyama S, et al: Correlation of c-erbB-2 protein expression and lymph node status in early gastric cancer. Oncology 49:363-367, 1992
47. Tsugawa K, Fushida S, Yonemura Y: Amplification of the c-erbB-2 gene in gastric carcinoma: Correlation with survival. Oncology 50:418-425, 1993
48. Jaehne J, Cordon-Cardo C, Albino A, et al: Pathogenic and prognostic relevance of HER2/neu in gastric carcinoma. Eur J Surg Oncol 20:362, 1994 (abstr)
49. Nakajima M, Sawada H, Yamada Y, et al: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85:1894-1902, 1999
50. Adam J: Statistical Know-How in Medical Research. Berlin, Germany, Ullstein Mosby GmbH&Co KG, 1992
51. Oghuri T, Sato Y, Koizumi W, et al: An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: Is the c-erbB-2 protein really a prognostic indicator? Int J Cancer 53:75-79, 1993
52. Yokota J, Yamamoto T, Toyoshima K, et al: Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1:765-767, 1986
53. ERBB expression and the gene amplification. Cancer Res 50:8002-8009, 1990
54. Falk V, Guillick W: c-erbB-2 oncogene product staining in gastric adenocarcinoma: An immunohistochemical study. J Pathol 159:107-111, 1989
55. Stern DF, Kamps MP, Cao H: Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo. Mol Cell Biol 8:3969-3973, 1988
56. Peles E, Lamprecht R, Ben-Levy R, et al: Regulated coupling of the Neu receptor to phosphatidylinositol 3′-kinase and its release by oncogenic activation. J Biol Chem 267:12266-12274, 1992
57. Luttrell DK, Lee A, Lansing TJ, et al: Involvement of pp60c-src with two major signalling pathways in human breast cancer. Proc Natl Acad Sci USA 1991:83-87, 1994
58. Satoh T, Endo M, Nakafuku M, et al: Accumulation of p21ras.GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity. Proc Natl Acad Sci USA 87:7926-7929, 1990
59. Sistonen L, Hölttä E, Lehväslaiho H, et al: Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase. J Cell Biol 109:1911-1919, 1989
60. Boyd D: Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line. Cancer Res 49:2427-2432, 1989
61. Allgayer H, Wang H, Wang Y, et al: Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2alpha-related factor. J Biol Chem 274:4702-4714, 1999
62. Kaufman PA, Guyre PM, Barth RJ, et al: Phase I trial of interferon gamma (IFN-γ) and MDX-210 (anti-HER-2/neu x anti FCγRI) in patients (pts) with metastatic carcinomas that overexpress HER-2/neu: Preliminary findings. Proc Am Soc Clin Oncol 16:430a, 1997 (abstr 1542)
63. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
64. Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998